137 related articles for article (PubMed ID: 16453193)
1. Switching from dorzolamide to brinzolamide: effect on intraocular pressure and patient comfort.
Inoue K; Wada SA; Wakakura M; Inoue J; Tomita G
Jpn J Ophthalmol; 2006; 50(1):68-9. PubMed ID: 16453193
[No Abstract] [Full Text] [Related]
2. Ocular comfort of brinzolamide 1.0% ophthalmic suspension compared with dorzolamide 2.0% ophthalmic solution: results from two multicenter comfort studies. Brinzolamide Comfort Study Group.
Silver LH
Surv Ophthalmol; 2000 Jan; 44 Suppl 2():S141-5. PubMed ID: 10665516
[TBL] [Abstract][Full Text] [Related]
3. The safety and efficacy of brinzolamide 1%/timolol 0.5% fixed combination versus dorzolamide 2%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension.
Sezgin Akçay Bİ; Güney E; Bozkurt KT; Unlü C; Akçali G
J Ocul Pharmacol Ther; 2013 Dec; 29(10):882-6. PubMed ID: 24180628
[TBL] [Abstract][Full Text] [Related]
4. Brinzolamide/timolol versus dorzolamide/timolol fixed combinations: A hospital-based, prospective, randomized study.
Galose MS; Elsaied HM; Macky TA; Fouad PH
Indian J Ophthalmol; 2016 Feb; 64(2):127-31. PubMed ID: 27050347
[TBL] [Abstract][Full Text] [Related]
5. The safety and efficacy of brinzolamide 1%/timolol 0.5% fixed combination versus dorzolamide 2%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension.
Manni G; Denis P; Chew P; Sharpe ED; Orengo-Nania S; Coote MA; Laganovska G; Volksone L; Zeyen T; Filatori I; James J; Aung T
J Glaucoma; 2009; 18(4):293-300. PubMed ID: 19365194
[TBL] [Abstract][Full Text] [Related]
6. [Innovative glaucoma therapy. Glaucoma therapy with topical carbonic anhydrase inhibitors].
Herkel U; Pfeiffer N
Ophthalmologe; 2001 Oct; 98(10):929-33. PubMed ID: 11699313
[TBL] [Abstract][Full Text] [Related]
7. Patients' acceptance of a switch from dorzolamide to brinzolamide for the treatment of glaucoma in a clinical practice setting.
Barnebey H; Kwok SY
Clin Ther; 2000 Oct; 22(10):1204-12. PubMed ID: 11110231
[TBL] [Abstract][Full Text] [Related]
8. Brimonidine tartrate 0.15%, dorzolamide hydrochloride 2%, and brinzolamide 1% compared as adjunctive therapy to prostaglandin analogs.
Bournias TE; Lai J
Ophthalmology; 2009 Sep; 116(9):1719-24. PubMed ID: 19592108
[TBL] [Abstract][Full Text] [Related]
9. [Mode of action, clinical profile and relevance of carbonic anhydrase inhibitors in glaucoma therapy].
Eichhorn M
Klin Monbl Augenheilkd; 2013 Feb; 230(2):146-9. PubMed ID: 23430679
[TBL] [Abstract][Full Text] [Related]
10. Comparison of ocular hypotensive effect and safety of brinzolamide and timolol added to latanoprost.
Miura K; Ito K; Okawa C; Sugimoto K; Matsunaga K; Uji Y
J Glaucoma; 2008; 17(3):233-7. PubMed ID: 18414111
[TBL] [Abstract][Full Text] [Related]
11. [Azarga, a new and useful fixed combination in glaucoma treatment].
Călugăru M; Călugăru D
Oftalmologia; 2011; 55(3):38-46. PubMed ID: 22428291
[TBL] [Abstract][Full Text] [Related]
12. The efficacy and safety of brinzolamide 1% ophthalmic suspension (Azopt) as a primary therapy in patients with open-angle glaucoma or ocular hypertension. Brinzolamide Primary Therapy Study Group.
Sall K
Surv Ophthalmol; 2000 Jan; 44 Suppl 2():S155-62. PubMed ID: 10665518
[TBL] [Abstract][Full Text] [Related]
13. Fixed topical combinations in glaucomatous patients and ocular discomfort.
Nebbioso M; Evangelista M; Librando A; Di Blasio D; Pescosolido N
Expert Opin Pharmacother; 2012 Sep; 13(13):1829-35. PubMed ID: 22770575
[TBL] [Abstract][Full Text] [Related]
14. Predictors for visual field progression and the effects of treatment with dorzolamide 2% or brinzolamide 1% each added to timolol 0.5% in primary open-angle glaucoma.
Martínez A; Sanchez-Salorio M
Acta Ophthalmol; 2010 Aug; 88(5):541-52. PubMed ID: 19799592
[TBL] [Abstract][Full Text] [Related]
15. Brinzolamide/brimonidine fixed-dose combination bid as an adjunct to a prostaglandin analog for open-angle glaucoma/ocular hypertension.
Topouzis F; Goldberg I; Bell K; Tatham AJ; Ridolfi A; Hubatsch D; Nicolela M; Denis P; Lerner SF
Eur J Ophthalmol; 2021 Jan; 31(1):103-111. PubMed ID: 31595773
[TBL] [Abstract][Full Text] [Related]
16. Short-term ocular tolerability of dorzolamide 2% and brinzolamide 1% vs placebo in primary open-angle glaucoma and ocular hypertension subjects.
Stewart WC; Day DG; Stewart JA; Holmes KT; Jenkins JN
Eye (Lond); 2004 Sep; 18(9):905-10. PubMed ID: 15002017
[TBL] [Abstract][Full Text] [Related]
17. The efficacy and safety of topical brinzolamide and dorzolamide when added to the combination therapy of latanoprost and a beta-blocker in patients with glaucoma.
Tsukamoto H; Noma H; Matsuyama S; Ikeda H; Mishima HK
J Ocul Pharmacol Ther; 2005 Apr; 21(2):170-3. PubMed ID: 15857284
[TBL] [Abstract][Full Text] [Related]
18. Comparing diurnal and nocturnal effects of brinzolamide and timolol on intraocular pressure in patients receiving latanoprost monotherapy.
Liu JH; Medeiros FA; Slight JR; Weinreb RN
Ophthalmology; 2009 Mar; 116(3):449-54. PubMed ID: 19157559
[TBL] [Abstract][Full Text] [Related]
19. The efficacy and safety of the timolol/dorzolamide fixed combination vs latanoprost in exfoliation glaucoma.
Konstas AG; Kozobolis VP; Tersis I; Leech J; Stewart WC
Eye (Lond); 2003 Jan; 17(1):41-6. PubMed ID: 12579169
[TBL] [Abstract][Full Text] [Related]
20. Brinzolamide--a new topical carbonic anhydrase inhibitor for glaucoma.
Med Lett Drugs Ther; 1998 Sep; 40(1036):95-6. PubMed ID: 9774966
[No Abstract] [Full Text] [Related]
[Next] [New Search]
